Increase Apparent Public Speaking Fluency By Speech Augmentation

Fluent and confident speech is desirable to every speaker. But professional speech delivering requires a great deal of experience and practice. In this paper, we propose a speech stream manipulation system which can help non-professional speakers to produce fluent, professional-like speech content, in turn contributing towards better listener engagement and comprehension. We propose to achieve this task by manipulating the disfluencies in human speech, like the sounds 'uh' and 'um', the filler words and awkward long silences. Given any unrehearsed speech we segment and silence the filled pauses and doctor the duration of imposed silence as well as other long pauses ('disfluent') by a predictive model learned using professional speech dataset. Finally, we output a audio stream in which speaker sounds more fluent, confident and practiced compared to the original speech he/she recorded. According to our quantitative evaluation, we significantly increase the fluency of speech by reducing rate of pauses and fillers

Unilateral pulmonary artery agenesis presenting with unilateral usual interstitial pneumonia in adulthood

Unilateral interstitial lung disease secondary to unilateral pulmonary artery agenesis (UPAA) is a rare anomaly due to a malformation of the sixth aortic arch of the affected side during embryogenesis. While most of the patients present in neonatal period with either cardiac anomalies or respiratory symptoms some of them can remain asymptomatic and late diagnosis is possible when suspicious presentation is noted on chest radiography. We report a case of 32-year female with a history of recurrent respiratory tract infection, who presented with cough and expectoration and the diagnosis of unilateral interstitial lung disease secondary to ipsilateral pulmonary interruption was made

Breast cancer management pathways during the COVID-19 pandemic: outcomes from the UK ‘Alert Level 4’ phase of the B-MaP-C study

From Springer Nature via Jisc Publications RouterHistory: received 2020-08-11, rev-recd 2020-12-04, accepted 2020-12-10, registration 2020-12-11, pub-electronic 2021-03-25, online 2021-03-25, pub-print 2021-05-25Publication status: PublishedAbstract: Background: The B-MaP-C study aimed to determine alterations to breast cancer (BC) management during the peak transmission period of the UK COVID-19 pandemic and the potential impact of these treatment decisions. Methods: This was a national cohort study of patients with early BC undergoing multidisciplinary team (MDT)-guided treatment recommendations during the pandemic, designated ‘standard’ or ‘COVID-altered’, in the preoperative, operative and post-operative setting. Findings: Of 3776 patients (from 64 UK units) in the study, 2246 (59%) had ‘COVID-altered’ management. ‘Bridging’ endocrine therapy was used (n = 951) where theatre capacity was reduced. There was increasing access to COVID-19 low-risk theatres during the study period (59%). In line with national guidance, immediate breast reconstruction was avoided (n = 299). Where adjuvant chemotherapy was omitted (n = 81), the median benefit was only 3% (IQR 2–9%) using ‘NHS Predict’. There was the rapid adoption of new evidence-based hypofractionated radiotherapy (n = 781, from 46 units). Only 14 patients (1%) tested positive for SARS-CoV-2 during their treatment journey. Conclusions: The majority of ‘COVID-altered’ management decisions were largely in line with pre-COVID evidence-based guidelines, implying that breast cancer survival outcomes are unlikely to be negatively impacted by the pandemic. However, in this study, the potential impact of delays to BC presentation or diagnosis remains unknown

Correction: Breast cancer management pathways during the COVID-19 pandemic: outcomes from the UK 'Alert Level 4' phase of the B-MaP-C study.

A Correction to this paper has been published: https://doi.org/10.1038/s41416-021-01378-

Correction: Breast cancer management pathways during the COVID-19 pandemic: outcomes from the UK ‘Alert Level 4’ phase of the B-MaP-C study

From Springer Nature via Jisc Publications RouterHistory: registration 2021-03-26, online 2021-04-12, pub-electronic 2021-04-12, pub-print 2021-08-31Publication status: PublishedA Correction to this paper has been published: https://doi.org/10.1038/s41416-021-01378-

Breast cancer management pathways during the COVID-19 pandemic: outcomes from the UK ‘Alert Level 4’ phase of the B-MaP-C study

Abstract: Background: The B-MaP-C study aimed to determine alterations to breast cancer (BC) management during the peak transmission period of the UK COVID-19 pandemic and the potential impact of these treatment decisions. Methods: This was a national cohort study of patients with early BC undergoing multidisciplinary team (MDT)-guided treatment recommendations during the pandemic, designated ‘standard’ or ‘COVID-altered’, in the preoperative, operative and post-operative setting. Findings: Of 3776 patients (from 64 UK units) in the study, 2246 (59%) had ‘COVID-altered’ management. ‘Bridging’ endocrine therapy was used (n = 951) where theatre capacity was reduced. There was increasing access to COVID-19 low-risk theatres during the study period (59%). In line with national guidance, immediate breast reconstruction was avoided (n = 299). Where adjuvant chemotherapy was omitted (n = 81), the median benefit was only 3% (IQR 2–9%) using ‘NHS Predict’. There was the rapid adoption of new evidence-based hypofractionated radiotherapy (n = 781, from 46 units). Only 14 patients (1%) tested positive for SARS-CoV-2 during their treatment journey. Conclusions: The majority of ‘COVID-altered’ management decisions were largely in line with pre-COVID evidence-based guidelines, implying that breast cancer survival outcomes are unlikely to be negatively impacted by the pandemic. However, in this study, the potential impact of delays to BC presentation or diagnosis remains unknown

Breast cancer management pathways during the COVID-19 pandemic: outcomes from the UK ‘Alert Level 4’ phase of the B-MaP-C study

Abstract: Background: The B-MaP-C study aimed to determine alterations to breast cancer (BC) management during the peak transmission period of the UK COVID-19 pandemic and the potential impact of these treatment decisions. Methods: This was a national cohort study of patients with early BC undergoing multidisciplinary team (MDT)-guided treatment recommendations during the pandemic, designated ‘standard’ or ‘COVID-altered’, in the preoperative, operative and post-operative setting. Findings: Of 3776 patients (from 64 UK units) in the study, 2246 (59%) had ‘COVID-altered’ management. ‘Bridging’ endocrine therapy was used (n = 951) where theatre capacity was reduced. There was increasing access to COVID-19 low-risk theatres during the study period (59%). In line with national guidance, immediate breast reconstruction was avoided (n = 299). Where adjuvant chemotherapy was omitted (n = 81), the median benefit was only 3% (IQR 2–9%) using ‘NHS Predict’. There was the rapid adoption of new evidence-based hypofractionated radiotherapy (n = 781, from 46 units). Only 14 patients (1%) tested positive for SARS-CoV-2 during their treatment journey. Conclusions: The majority of ‘COVID-altered’ management decisions were largely in line with pre-COVID evidence-based guidelines, implying that breast cancer survival outcomes are unlikely to be negatively impacted by the pandemic. However, in this study, the potential impact of delays to BC presentation or diagnosis remains unknown

The Unprotected: Characteristics of Older Adults Who Did Not Receive Their Annual Influenza Immunization

The Centers for Disease Control and Prevention (CDC) estimate that influenza causes 36,000 deaths in the United States every year, and results in direct medical care costs of over $4.6 billion annually. Influenza and pneumonia are responsible for 8,800 deaths per year in California alone, making it the sixth leading cause of death among adults in the state, yet the illnesses are largely preventable by immunization.The California Adult Immunization Coalition (CAIC) is comprised of more than 20 organizations across California who are working together to increase immunization rates for influenza and pneumonia in adults. The CAIC analyzed influenza vaccination rates in California using data from the 2001 California Health Interview Survey (CHIS), and compared the results to the national Healthy People 2010 goals for adult immunization. The national goals specify that 90% of older adults (age 65 and over) should be immunized against influenza annually by the year 2010 (i.e., less than 10% should remain unimmunized).To deepen our understanding of this important public health issue, the CAIC has added several specific questions concerning adult immunizations to the 2003 CHIS survey. Results of this most recent survey will be available next year. Increasing California’s adult immunization rates to reach the national goal requires the persistent efforts of multiple sectors including vaccine suppliers, health departments, and individual health clinics and health providers’ offices.Key findings are:• 32.6% of older adults (age 65 and over) in California for whom annual flu shots are recommended did not get immunized in 2001. • Immunization rates among older adults varied by region; rates were found to be lowest in the Los Angeles region (63.9%) and highest in the Sacramento region (77.0%). However, no regions in California came close to meeting the national goal that 90% of older adults be immunized against influenza. • Although there was a strong age-related trend for the elderly to get an influenza immunization, 27% remained unimmunized even among people aged 75 years and over. • Among the state’s racial and ethnic groups, Latinos (46%) and African Americans (47%) over the age of 65 were almost twice as likely to go unimmunized when compared with Asians (27%) and Whites (28%) in the same age group. • Persons with a "medical home" (a regular place to get medical care) were more than twice as likely to get immunized compared to those who did not have a usual source of care. • The more often an individual saw the doctor, the more likely he or she was to get a flu shot, however, large numbers of people with regular access to care were still unimmunized. • Patients covered by Medicare were immunized more often than those who were not covered; in the Medicare-covered group 32.7% were not immunized. • There were no differences found in immunization rates between women and men